Navigation Links
FDA Cancer Drug Approval Rate Highlighted in JNCI

Agency Analysis: More than 50 new cancer indications approved over a 32-month period

SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration's Office of Oncology Drug Products approved more than 50 new indications for the use of oncology and hematology drugs and biologics between July 2005, when the office began reviewing marketing applications, and the end of 2007, according to a new agency study.

(Logo: )

During the time period, the office reviewed 60 applications from companies seeking approval to treat people with 30 different types of cancer, including breast, lung, colon, kidney, head and neck and several forms of blood cancer.

The Office of Oncology Drug Products, part of the Center for Drug Evaluation and Research (CDER), took action on 58 of the applications, approving 53 new cancer indications. Five applications were not approved, and two applications were withdrawn before any regulatory action was taken. These approved applications included indications for 18 new drugs that had not been previously approved and 35 additional indications for already approved drugs.

"Our reviews during this period focused on approving new or existing treatments based on treatment effect, patient safety, and the treatment's risk-benefit profile," said Rajeshwari Sridhara, Ph.D., lead author of the FDA analysis.

"We also considered the patient populations in need of additional treatment options, existing treatments, and whether this was a new molecular entity," said Sridhara, an acting division director, in CDER's Office of Biostatistics.

The FDA's retrospective analysis appears in the Feb. 24, 2010, issue of the Journal of the National Cancer Institute. The journal article is available now at

Approval data from July 1, 2005 through Dec. 31, 2007 were reviewed by the authors for this analysis. This review was started after the formation of the Office of Oncology Drug Products and the implementation in 2007 of the Food and Drug Administration Amendments Act (FDAAA). The review included indications for both conventional oncology drugs and biological oncology products reviewed in CDER. It did not include products reviewed in other FDA centers.

"The FDA used a variety of trial designs and endpoints in approving these applications. In addition, we implemented recent regulatory initiatives including accelerated approval and priority reviews to expedite the approval of these indications," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, and one of the review's co-authors.

The accelerated approval process allows for earlier approval of drugs to treat serious diseases with an unmet medical need and is based on a surrogate endpoint, a laboratory measurement or physical sign that is used in clinical trials as an indirect measurement of clinical benefit. Under an accelerated approval, the FDA approves the drug on the condition that the drug manufacturer conducts further studies to evaluate the drug's actual clinical benefit. Priority reviews are conducted within six months, whereas other reviews are usually reviewed in 10 months.

Other highlights from the cancer drug approvals review include:

  • New treatments were approved for six of the seven most deadly forms of cancer in the United States (lung, colon, breast, ovarian, cervical and pancreatic)
  • 35 of the approvals were existing products seeking new treatment indications
  • New molecular entities represented 18, or 34 percent, of the 53 approvals
  • Approvals included treatments for pediatric patients, supportive care indications aimed at improving the side effects of cancer therapies, and treatment options for rare diseases  
  • Three new treatments were approved for advanced kidney cancer
  • Nine drugs received accelerated approval, a regulatory mechanism allowing the FDA to approve a drug with subsequent studies performed after approval to demonstrate an effect on survival or other clinically meaningful endpoints
  • Twenty five percent of the indications approved were based on improvement in overall survival or improvement in both progression-free survival and overall survival

Other authors of the review include: John R. Johnson, M.D., Clinical Team Leader, Robert Justice, M.D., director of the Division of Drug Oncology Products, Patricia Keegan, M.D., director of the Division of Biologic Oncology Products and Aloka Chakravarty, Ph.D., acting division director, Division of Biometrics VII, Office of Biostatistics.

For more information:

FDA Office of Oncology Drug Products

Food and Drug Administration Amendments Act (FDAAA)

Journal of the National Cancer Institute

Media Inquiries: Erica Jefferson, 301-796-4988,

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top



SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists Spot Genetic Fingerprints of Individual Cancers
2. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
3. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
4. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
5. Personalizing cancer: Creating biomarkers from tumor DNA
6. Chemical tags likely to affect metabolism, cancer development
7. FDA Approved Diabetes Drug Despite Hints at Cancer Risk
8. VARI findings may help patients with deadly kidney cancer
9. Drug for advanced kidney cancer shrinks tumors prior to surgery
10. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
11. Researchers chart genomic map spanning over 2 dozen cancers
Post Your Comments:
(Date:10/10/2015)... ... October 10, 2015 , ... The Bank of America 500 NASCAR Sprint ... Saturday, October 10th, defending race winner, Kevin Harvick, will battle it out for ... Jr., and all of the stars of the NASCAR Sprint Cup Series. As ...
(Date:10/10/2015)... ... October 10, 2015 , ... Attending ... the health of men, women and children. Depending on the school, the exact ... to the medical field. , Students in a medical school must complete undergraduate ...
(Date:10/10/2015)... Philadelphia, PA (PRWEB) , ... October 10, 2015 ... ... Newman, Wigrizer, Brecher & Miller is pleased to be recognized by The National ... Lawyers. This list acknowledges the 50 law firms across the United States who ...
(Date:10/9/2015)... ... October 09, 2015 , ... Doctors on Liens ... Fresno , to provide highly needed medical care to personal injury victims. When ... providers to diagnose, document and treat the variety of conditions ailing them. With ...
(Date:10/9/2015)... ... October 09, 2015 , ... Each year, over ... the pre-eminent organization in global health: the World Health Organization (WHO). At its ... These internships are a mechanism for WHO to help build public health capacity ...
Breaking Medicine News(10 mins):
... A new $10 million research project which aims at ... launched by the Preventative Health //Flagship, a CSIRO program ... on the early detection of Alzheimer's disease, which currently ... researchers will be using Positron Emission Tomography (PET scans) ...
... screening appears to be increasing among Veterans Affairs patients, ... screening procedures// , according to a report. A second ... with other illnesses and reduced life expectancies may not ... harmed, but continue to be screened at high rates. ...
... have come up with incriminating evidence that warns non-vegetarians who ... study has pointed out that eating more than one and ... developing hormone related breast cancer and another study that ... heart from heart diseases except for vitamin C which seems ...
... the remedy of choice for treatment of influenza is causing ... side effects, regulators said today. ,The U.S. FDA has ... and mental disorientation were reported from Japan by people who ... reports concerned children. ,The new label approved by ...
... patients will adhere more closely to their medication regimens ... care program that includes patient education, specially packaged medications, ... ,The “Federal Study of Adherence to Medications in the ... Health-System Pharmacists (ASHP) Research and Education Foundation, followed 200 ...
... onset of diabetes today is linked to high stress levels. ... diet, hypertension and lack of physical exercise. The number of ... crores and about 7.2 lakh lives are claimed by this ... realize consequences of this deadly disease. , ,Because ...
Cached Medicine News:
(Date:10/9/2015)... Oct. 9, 2015 Regulatory affairs groups within medical ... --> --> These specialized groups are charged ... of global regulations pertaining to the development and marketing of ... groups largely rely on their own internal effectiveness and efficiencies ... --> --> Optimal ...
(Date:10/9/2015)... 9, 2015 ® ... einer Kolonoskopie im Rahmen eines Screenings, einer ... NOCT-Studie bewertete auch die Compliance, Sicherheit, Patientenakzeptanz ... ® ) an erwachsenen Patienten vergleicht, die ... einer beobachtenden oder einer diagnostischen Kolonoskopie unterziehen. ...
(Date:10/9/2015)... , October 9, 2015 ... of major players. --> India ... --> announces addition of 3 ... and 2020 forecasts for global markets as well ... along with analysis of major players. ...
Breaking Medicine Technology:
... in Mice Transgenic for Human TNFa, LAUSANNE, ... (Debiopharm), a global independent biopharmaceutical,development company specialising ... presentation of preclinical results that,validate the mechanism ... vaccine, that inhibits inflammatory processes in animal,models ...
... 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned ... strong positive,results in studies of vaccines against ... proprietary AIPwLV(TM) vaccine technology. The,studies were conducted ... (CMB), the Contract Research Organization led by ...
Cached Medicine Technology:
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: